Ocugen Shareholders Face Two Clocks: A December Vote and a 2027 Data Run

Ocugen has handed investors a pair of deadlines that pull in opposite directions. One is a corporate housekeeping matter with a fixed date — a rescheduled extraordinary general meeting on December 22, 2026, where shareholders will vote on raising the authorized common stock by 250,000,000 shares. The other is a clinical calendar stretching into 2027, when the company expects to learn whether its lead gene-therapy programs justify the money already spent on them.

The financing question sits between those two poles, and management has framed it in unusually blunt terms.

$84.6 Million and a Going-Concern Caveat

In its third-quarter 2026 report, Ocugen put its holdings of cash, cash equivalents, restricted cash and short-term investments at $84.6 million. Management projected that this sum would fund operations through 2028.

That forecast implies room to maneuver — provided the assumptions behind it hold. The same quarterly filing, however, carried a going-concern warning: management concluded there was substantial doubt about the company's ability to continue as a going concern within one year of the financial statements' publication. Investors therefore have to weigh a forward-looking runway estimate against an explicitly declared uncertainty, and treat the 2028 horizon as a management projection rather than a certainty.

Three Programs, Two Readouts

The clinical story is what the bullish case rests on. At the Stifel healthcare conference, management presented its outlook for three late-stage ophthalmology programs, according to media reports. Summary Phase 3 data for OCU400 are expected in the first quarter of 2027, with OCU410ST results following in the second quarter of 2027. That staggered sequence gives investors separate decision points — assuming Ocugen hits the announced windows.

OCU400 carries the heavier weight simply because it reports first. A convincing result would support the program's further development and give the economic case some clinical substance; a weak one would force a more cautious read on the program's commercial prospects. Dosing has already begun in the Phase 3 trial of OCU410, and OCU410 and OCU410ST must be assessed as distinct programs.

Regulatory groundwork is also in place. The quarterly report disclosed a provisional approval and a priority designation for OCU400 in the Bahamas — a regulatory foothold rather than a commercial verdict.

Celairis Deal Ties Income to Trial Outcomes

Ocugen's licensing arrangement with Celairis Therapeutics adds a commercial dimension to the same clinical bets. The exclusive license covers Australia, New Zealand and several Southeast Asian markets, including the ASEAN region. Under the agreement, Ocugen can receive up to $7.1 million in upfront and potential development and milestone payments, plus high-single-digit percentage royalties on net sales and 50% of regional gross profits.

The structure splits responsibilities: Celairis handles regional regulatory filings, market access and commercialization, while Ocugen expects to manufacture and supply the therapy. One milestone — a $1.0 million payment — is tied to Australian approval, and another payment depends on positive topline results from the Phase 3 LiMeliGhT study. Those conditions mean the potential inflows arrive only if clinical and regulatory progress opens the path to market; delays or failures would push the corresponding receipts further out.

What the December Vote Actually Changes

The share-count proposal on the December 22 ballot does not alter the clinical or financial facts on its own. Approval would widen the headroom for future equity issuance, and if Ocugen draws on that headroom, existing holders' stakes would be diluted. That makes the vote a signal about how management intends to bridge the gap between its projected runway and the cost of running three late-stage programs.

For shareholders, the calculus comes down to whether the development pipeline can be carried on the funding currently available. If the runway holds and the programs advance, the optimistic analyst stance can be supported operationally. If financing comes under pressure, capital measures move to the center of the story.

The near-term schedule is now clear: a shareholder vote in December, OCU400 Phase 3 data in the first quarter of 2027, and OCU410ST results in the second. Whether investors position themselves ahead of those readouts or wait for the data depends on how much weight they place on a runway that management itself has flagged as uncertain.